Therapeutic potency of oncolytic virotherapy-induced cancer stem cells targeting in brain tumors, current status, and perspectives.


Journal

Journal of cellular biochemistry
ISSN: 1097-4644
Titre abrégé: J Cell Biochem
Pays: United States
ID NLM: 8205768

Informations de publication

Date de publication:
03 2019
Historique:
received: 29 03 2018
accepted: 21 08 2018
pubmed: 16 10 2018
medline: 18 6 2020
entrez: 16 10 2018
Statut: ppublish

Résumé

Brain tumors are the most common form of solid tumors in children and is presently a serious therapeutic challenge worldwide. Traditional treatment with chemotherapy and radiotherapy was shown to be unsuccessful in targeting brain tumor cancer stem cells (CSCs), leading to recurrent, treatment-resistant secondary malignancies. Oncolytic virotherapy (OV) is an effective antitumor therapeutic strategy which offers a novel, targeted approach for eradicating pediatric brain tumor CSCs by utilizing mechanisms of cell killing that differ from conventional therapies. A number of studies and some clinical trials have therefore investigated the effects of combined therapy of radiations or chemotherapies with oncolytic viruses which provide new insights regarding the effectiveness and improvement of treatment responses for brain cancer patients. This review summarizes the current knowledge of the therapeutic potency of OVs-induced CSCs targeting in the treatment of brain tumors for a better understanding and hence a better management of this disease.

Identifiants

pubmed: 30321455
doi: 10.1002/jcb.27661
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2766-2773

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Amirhossein Bahreyni (A)

Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Elnaz Ghorbani (E)

Department of Microbiology, Al-Zahra University, Tehran, Iran.

Hamid Fuji (H)

Department of Biochemistry, Payame-Noor University, Mashhad, Iran.

Mikhail Ryzhikov (M)

Division of Pulmonary and Critical Care Medicine, Washington University, School of Medicine, Saint Louis, Missouri.

Majid Khazaei (M)

Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Marjan Erfani (M)

Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.

Amir Avan (A)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Seyed M Hassanian (SM)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Kayhan Azadmanesh (K)

Virology Department, Pasteur Institute of Iran, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH